Definium Therapeutics (DFTX) Change in Accured Expenses (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Change in Accured Expenses data on file, last reported at $3.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $3.0 million, up 325.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.3 million (up 129.64% YoY), and the FY2025 annual result was $6.0 million, up 92.01% from the prior year.
• Change in Accured Expenses advanced to $3.0 million in Q1 2026 per DFTX's latest filing, from $923000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.8 million in Q4 2024 and troughed at -$2.7 million in Q1 2024.
• A 5-year average of $997470.6 and a median of $990000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 1677.23% in 2023, then slumped 484.5% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$1.0 million in 2022, then soared by 251.83% to $1.6 million in 2023, then soared by 140.23% to $3.8 million in 2024, then slumped by 75.62% to $923000.0 in 2025, then jumped by 224.38% to $3.0 million in 2026.
• Business Quant data shows DFTX's Change in Accured Expenses at $3.0 million in Q1 2026, $923000.0 in Q4 2025, and $3.4 million in Q3 2025.